Elif Oral, MD, Professor at the University of Michigan, discusses advances in lipodystrophy research presented at ENDO 2026.
Lipodystrophies are rare metabolic disorders characterized by the loss of adipose tissue. This leads to complications such as insulin resistance, diabetes mellitus, hypertriglyceridemia, and fatty liver. Lipodystrophies generally begin in childhood and have an underlying autoimmune component associated with its etiology. The disorder can be genetic or acquired. Symptoms that may indicate lipodystrophy include thin arms and legs, prominent muscular veins, cutaneous fat around the abdomen, and difficult to treat diabetes. Current management of patients includes cosmetic surgery, diet, and drug therapy for control of diabetes and dyslipidemia. Leptin replacement therapy is the only lipodystrophy-specific treatment.
New research presented at ENDO 2026 highlighted progress in the treatment, diagnosis, and clinical understanding of lipodystrophy, with studies examining long-term metreleptin therapy, ongoing clinical trials in partial lipodystrophy, disease characterization, and new approaches to earlier diagnosis.
Long-term findings from a 36-month phase 4 study evaluated the immunogenicity of metreleptin in patients with generalized lipodystrophy (GL). Although most participants developed anti-drug antibodies and transient neutralizing antibody activity, these responses generally declined over time and did not appear to have a lasting impact on treatment safety or metabolic efficacy. The findings provide additional reassurance regarding the long-term use of metreleptin despite the development of immune responses.
Researchers also presented baseline data from the METRE-PL phase 3 trial, the first randomized, placebo-controlled study evaluating metreleptin in familial partial lipodystrophy (FPLD). The enrolled population demonstrated a substantial metabolic disease burden, with nearly all patients having diabetes or hypertriglyceridemia and many experiencing complications such as pancreatitis and diabetic neuropathy. The ongoing trial will determine whether metreleptin can improve glycemic control and triglyceride levels in this underserved patient population.
Data from the LD-Lync natural history study revealed important differences between acquired and genetic forms of lipodystrophy. While patients with genetic lipodystrophy experienced higher rates of metabolic complications—including hypertriglyceridemia, fatty liver disease, and polycystic ovary syndrome—those with acquired lipodystrophy were more likely to have autoimmune disorders, inflammatory conditions, and cancer, often diagnosed at younger ages. These findings emphasize the need for subtype-specific management strategies, including greater attention to cancer surveillance and immune evaluation in acquired disease.
Finally, investigators from the RADIANT study reported a new clinical prediction model designed to identify lipodystrophy among patients with atypical diabetes using routinely collected clinical and laboratory data. The model demonstrated high specificity while maintaining good sensitivity after threshold adjustment, suggesting it could serve as an effective screening tool to help clinicians recognize patients who may benefit from specialized evaluation and genetic testing. Researchers noted that future refinements incorporating biomarkers and genomic data may further improve diagnostic accuracy.
Together, these studies presented at ENDO 2026 underscore continued progress in improving the diagnosis and management of lipodystrophy. From supporting the long-term safety profile of metreleptin to advancing clinical trials, refining disease characterization, and developing practical screening tools, the research reflects a growing effort to enable earlier diagnosis and more personalized care for patients with these rare disorders.
To learn more about lipodystrophy and other rare metabolic disorders, visit https://checkrare.com/diseases/metabolic-disorders/